Inferra AI / Company / ANAB
Anaptysbio, Inc.
ANAB · Health Care
Last earnings Sep 21, 2026
Key results
Collaboration revenuequarter
$22.3 million
Collaboration revenue was $22.3 million and $50.0 million for the three and six months ended June 30, 2025, compared to $11.0 million and $18.2 million for the three and six months ended June 30, 2024.
SEC original ↗Anaptysbio, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Revenuequarter
$9.7 million
This was due primarily to Jemperli royalties increasing $11.0 million and $22.1 million for the three and six months ended June 30, 2025 and $9.7 million in revenue recognized for the Vanda license agreement.
SEC original ↗Anaptysbio, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Collaboration revenue | $22.3 million | — | — |
| Revenue | $9.7 million | — | — |
Guidance · company-stated
No guidance located in the held release
“Anaptys estimates Sagard will have accrued ~$301 million in royalties and sales milestones through Q2 2026 and anticipates paydown of the remaining ~$299 million non-recourse debt monetization in the second half of 2027 •”
Capital allocation
Available-for-Sale Investments We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.
14 Stock Repurchase Program In March 2025, our Board of Directors authorized a stock repurchase program (the 2025 Repurchase Program ) to repurchase up to $ 75.0 million of our outstanding common stock.
Event summary
Anaptysbio, Inc. — Earnings release (2025-08-06)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Available-for-Sale Investments We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
14 Stock Repurchase Program In March 2025, our Board of Directors authorized a stock repurchase program (the 2025 Repurchase Program ) to repurchase up to $ 75.0 million of our outstanding common stock.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
In November 2025, our Board of Directors authorized an amendment to the 2025 Repurchase Program, under which an additional $ 100.0 million of our outstanding common stock may be repurchased .
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
During the three months ended March 31, 2026 , there were no repurchases made and the 2025 Repurchase Program expired on March 31, 2026 .
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
In March 2026, our Board of Directors authorized a stock repurchase program (the 2026 Repurchase Program ) to repurchase up to $ 100.0 million of our outstanding common stock.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
As of March 31, 2026 , $ 100.0 million remained available for future shares of common stock to be repurchased under the 2026 Repurchase Program.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
Strategy & priorities
(Nasdaq ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
SEC original ↗Anaptysbio, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
About Anaptys Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases.
SEC original ↗Anaptysbio, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Prior to the separation described below, we were a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
Risks & headwinds
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements.
SEC original ↗Anaptysbio, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 29 Item 1A.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
We are currently party to litigation with GSK with respect to the GSK Agreement.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
Legal Proceedings for additional information.
SEC original ↗Anaptysbio, Inc. — 10-Q Quarterly report10-QMay 12, 2026
Earnings deck slides
0 decks with slide viewAnaptysbio, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Anaptysbio, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 8-KANAB
Sep 21, 2026
- 8-KANAB
Aug 11, 2026
- 8-KANAB
Jul 30, 2026
- Q1 2026
- 8-KANAB
Jun 22, 2026
- 8-KANAB
May 29, 2026
- 8-KANAB
May 21, 2026
- 8-KANAB
May 12, 2026
- 10-QANAB
May 12, 2026
- 8-KANAB
May 11, 2026
- 8-K/AANAB
Apr 24, 2026
- 8-KANAB
Apr 20, 2026
- Q4 2025
- 8-KANAB
Mar 27, 2026
- 8-KANAB
Mar 3, 2026
- 10-KANAB
Mar 3, 2026
- 8-KANAB
Jan 9, 2026
- Q3 2025
- 8-KANAB
Nov 26, 2025
- 8-KANAB
Nov 21, 2025
- 8-KANAB
Nov 21, 2025
- 8-KANAB
Nov 10, 2025
- 8-KANAB
Nov 4, 2025
- 10-QANAB
Nov 4, 2025
- 8-KANAB
Oct 14, 2025
- Q2 2025
- 8-KANAB
Sep 29, 2025
- 8-KANAB
Aug 6, 2025
- 10-QANAB
Aug 6, 2025
- Q1 2025
- 8-KANAB
Jun 17, 2025
- 8-KANAB
Jun 3, 2025
- 8-KANAB
May 5, 2025
- 10-QANAB
May 5, 2025
- Q4 2024
- 8-KANAB
Mar 24, 2025
Earnings releases
7 documentsPresentations
2 documents
Transcripts
0 documentsNo transcripts for Anaptysbio, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.